TrialPanorama/Dataset huggingface dataset:
Please select the outcome measures that correspond to the clinical trial below.
Title: Actos Now for Prevention of Diabetes (ACT NOW)
Brief Summary: The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus


Options:
A: Prevention of Type 2 Diabetes (2.4 years)
B: Change in Reactive Hyperemic Index Over the 3-month Treatment Period (Change from baseline to 3 months)
C: ß-cell Response Measured by Hyperglycemic Clamp (3-months after medication washout (Month 15)); M/I (3-months after a medication washout)
D: Change in area under the 0-2 hour prandial glucose curve at 12 weeks

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Internet-Based Cholesterol Assessment Trial
Brief Summary: The purpose of this trial is to find out if a special website might help people discover if they have high cholesterol and then enable them to manage their cholesterol more appropriately. The primary aim of this trial is to determine the effects on consumers' use of cholesterol lowering therapy of an online service that provides automated, individually tailored, advice about eligibility for cholesterol lowering treatment. The primary null hypothesis being tested is that the service will result in no change in the use of cholesterol lowering treatments by consumers that use the service.

The secondary aim of the trial is to see if it is possible to improve the cholesterol management of the friends or relatives of consumers that use the I-CAT service. The corresponding secondary null hypothesis being tested is that the I-CAT service will result in no change in the use of cholesterol lowering treatments by the friends or relatives of the consumers that use the service.


Options:
A: Percentage (%) change from baseline to week 24 in serum LDL-C levels. (24 weeks from Baseline)
B: Feasibility of subject recruitment; feasibility of delivery of the CHD intervention and surveys in a busy practice setting; feasibility of measuring study outcomes (Measured at the end of the study period (approximately 2 years))
C: Discussion with provider about CHD risk reduction; Stated plans for CHD risk reduction
D: To determine the effectiveness of a consumer-mediated, Internet-based strategy for identification and intervention in hypercholesterolemia.

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.
Brief Summary: The primary aim of the study is to compare the effects of the two blood glucose targets on 90 day all-cause mortality in Intensive Care patients who are predicted on admission to stay in the ICU for at least one full calendar day. The hypothesis is that there is little difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/L, and those assigned a glucose range of less than 10.0 mmol/L with insulin being infused if blood glucose exceeds 10.0 mmol/L, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/L.


Options:
A: mortality
B: Mortality (28 day); Morbidity (mean sepsis-related organ failure assessment [SOFA] score during intensive care unit length of stay [ICU LOS])
C: Mortality; Sternal wound infections; Stroke; Cardiac arrhythmias; Renal failure
D: all-cause mortality (90 days)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Multi-Center, Open Label Randomized Stratified Controlled Trial of the Effects of Blood Glucose Management on 90-Day All-Cause Mortality in a Heterogenous Population of Intensive Care Unit (ICU) Patients.
Brief Summary: The primary aim of the study is to compare the effects of the two blood glucose targets on 90 day all-cause mortality in Intensive Care patients who are predicted on admission to stay in the ICU for at least one full calendar day. The hypothesis is that there is little difference in the relative risk of death between patients assigned a glucose range of 4.5 - 6.0 mmol/L, and those assigned a glucose range of less than 10.0 mmol/L with insulin being infused if blood glucose exceeds 10.0 mmol/L, and adjusted when needed to maintain blood glucose of 8.0 - 10.0 mmol/L.


Options:
A: all-cause mortality (90 days)
B: Reduction of the mortality rate of ARDS patients at d90 (36 months)
C: mortality
D: Effect of early IVIG versus placebo on CIPNM on day 14 (day 14)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)
B: Mean running time of a maximum of two consecutive haemodialysis circuits (seven days starting at time of HIT suspicion)
C: The filter survival time of AN69ST and AN69 membrane hemofilter in each CRRT process (6 months); The number of patients with early filter clotting in the scheduled CRRT using AN69ST and AN69 membrane hemofilter (6 months); The number of patients in AN69ST and AN69 hemofilter group according to the final filter clotting grading (6 months)
D: Time of insertion without complication

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)
B: Overall survival (60 days)
C: We will study the feasibility of recruiting ther target population, administering the study therapies according to pre-defined protocols and following patients for clinical endpoints. (60 days)
D: Renal replacement therapy proportion (28 days)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Mean daily dialysis delivered dose during intensive care stay (dialysis days during intensive care stay)
B: Duration of event-free survival of the first non-tunneled hemodialysis catheter (defined at the time in days from catheter insertion to withdrawal whatever the reason) (up to 28 days)
C: Number of filters used per hour (24 months)
D: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Death from all causes at 30 days after randomisation (30 days)
B: all-cause mortality. (28-day)
C: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)
D: 60-day All-cause Mortality (60 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: all-cause mortality. (28-day)
B: 60-day All-cause Mortality (60 days)
C: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)
D: Death from all causes at 30 days after randomisation (30 days)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)
B: Number of filters used per hour (24 months)
C: CRRT-filter life span in hours (during continuous renal replacement therapy up to 1 year); Overall survival in a 90day follow-up period (90 days)
D: Mean daily dialysis delivered dose during intensive care stay (dialysis days during intensive care stay)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Multicentre, Unblinded, Open Label, Randomised, Controlled Trial to Assess the Effect of Augmented Vs. Normal Continuous Renal Replacement Therapy (CRRT) on 90-Day All-Cause Mortality of Intensive Care Unit Patients With Severe Acute Renal Failure (ARF).
Brief Summary: This study seeks to determine if increasing the dose of continuous renal replacement therapy (CRRT) reduces 90-day all cause mortality in Intensive Care Unit (ICU) patients with severe acute renal failure (ARF).


Options:
A: Overall survival (60 days)
B: Death from all causes at 90 days after randomisation. (Within 90 days after randomisation)
C: We will study the feasibility of recruiting ther target population, administering the study therapies according to pre-defined protocols and following patients for clinical endpoints. (60 days)
D: Accumulation of anti-Xa activity in plasma and removal of anti-Xa activity by filtration. (24 hours)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Phase I / II Clinical Trial Regarding Vascular Regeneration Therapy by Transplantation of Autologous Peripheral Blood Endothelial Progenitor Cells (CD34+ Cells) in No-Option Patients With Chronic Critical Limb Ischemia
Brief Summary: The purpose of this study is to determine if stem cell therapy with one's own cells (autologous cells) delivered intramuscularly to one's leg with ulcer and/or gangrene due to poor blood flow will be safe and if it will relieve leg pain, increase blood flow, and/or cure the leg wound.


Options:
A: side effects (3months)
B: Major amputation
C: Survival without major amputation (6 months after implantation)
D: Number of participants with treatment-related adverse events occurring during the enrollment period as assessed by the Investigator using the MeDRA scale. (Primary follow up in a 6 month period)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: A Prospective, Randomized, Cross-over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors
Brief Summary: The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.


Options:
A: Evaluate the efficacy, safety and pharmacoeconomic of long-term secondary prophylaxis with Kogenate Bayer in comparison to on-demand treatment with Kogenate Bayer in terms of joint bleeding episodes per year (Every 6 months)
B: Incidence of Inhibitory Antibodies Against Factor IX Defined as Titre Equal to or Above 0.6 BU (Bethesda Units) (52 weeks after treatment start for patients on prophylaxis); Incidence of Inhibitory Antibodies Against Factor IX Defined as Titre Equal to or Above 0.6 BU (Bethesda Units) (28 weeks after treatment start on on-demand treatment)
C: Annualized Number of Bleeding Episodes (Baseline up to Week 56)
D: Number of Bleeds During 6 Month Treatment Period (6 months)

Answer: D
Please select the outcome measures that correspond to the clinical trial below.
Title: A Home Based Resistance Training Program for Obese Adults With Type 2 Diabetes
Brief Summary: This study will investigate the biological and psychosocial benefits of a home-based resistance-training program for sedentary, obese adults living with type 2 diabetes.


Options:
A: HbA1c (3 months)
B: Systolic blood Pressure (Baseline and 12 months); Glycated haemoglobin (HbA1c) (Baseline and 12 months)
C: HbA1c; Muscular strength
D: Hemoglobin A1c (12 months); Systolic Blood Pressure (12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Physical Activity Promotion in Breast Cancer Survivors: A Population Based Randomized Controlled Trial
Brief Summary: Over 30 studies have shown that exercise can improve physical fitness, reduce fatigue, increase functioning, and enhance overall quality of life (QoL) in breast cancer survivors both during and after treatments. Research has also shown, however, that breast cancer survivors experience a significant reduction in physical activity during treatments that is not recovered even years after treatments are completed. The objectives of this study are to examine the effects of two behavior change interventions (a step pedometer and printed materials) on physical activity, social cognitive variables, and QoL in a population-based sample of breast cancer survivors. Approximately 300 breast cancer survivors living in Northern Alberta will be randomized to one of four groups: (1) an exercise recommendation only group (viewed as the current standard of care), (2) an exercise recommendation plus pedometer group, (3) an exercise recommendation plus printed materials group, and (4) an exercise recommendation plus pedometer and printed materials group. Our primary hypothesis is that participants receiving the combined pedometer and printed materials intervention will report the greatest change in physical activity. Our secondary hypotheses are that these interventions will also result in improved QoL and more positive social cognitive beliefs about exercise in breast cancer survivors. Given the geographic dispersion of our population, finding practical and sustainable interventions that employ distance medicine-based approaches may be ideal for promoting healthy activity patterns in breast cancer survivors in Northern Alberta.


Options:
A: Quality of life (Participants will be followed over 8 weeks)
B: quality of life, fatigue, and body weight (baseline, 6 months, 12 months)
C: Exercise behavior
D: Change from Baseline in Arthralgia Severity (6 months); Change from Baseline in Arthralgia Severity (12 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Physical Activity Promotion in Breast Cancer Survivors: A Population Based Randomized Controlled Trial
Brief Summary: Over 30 studies have shown that exercise can improve physical fitness, reduce fatigue, increase functioning, and enhance overall quality of life (QoL) in breast cancer survivors both during and after treatments. Research has also shown, however, that breast cancer survivors experience a significant reduction in physical activity during treatments that is not recovered even years after treatments are completed. The objectives of this study are to examine the effects of two behavior change interventions (a step pedometer and printed materials) on physical activity, social cognitive variables, and QoL in a population-based sample of breast cancer survivors. Approximately 300 breast cancer survivors living in Northern Alberta will be randomized to one of four groups: (1) an exercise recommendation only group (viewed as the current standard of care), (2) an exercise recommendation plus pedometer group, (3) an exercise recommendation plus printed materials group, and (4) an exercise recommendation plus pedometer and printed materials group. Our primary hypothesis is that participants receiving the combined pedometer and printed materials intervention will report the greatest change in physical activity. Our secondary hypotheses are that these interventions will also result in improved QoL and more positive social cognitive beliefs about exercise in breast cancer survivors. Given the geographic dispersion of our population, finding practical and sustainable interventions that employ distance medicine-based approaches may be ideal for promoting healthy activity patterns in breast cancer survivors in Northern Alberta.


Options:
A: Changes in body composition, waist circumference, blood pressure, and serum levels of insulin, glucose, lipids, C-reactive protein, and HbA1c (At week 16); Improvement of physical fitness, cardiorespiratory fitness, and muscle strength (At week 16); Feasibility of a supervised exercise program for cancer survivors (At week 16); Maintain positive benefits of an exercise intervention (12 weeks post-intervention)
B: Physical activity questionnaire (International Physical Activity Questionnaire) (Baseline and 6 months)
C: Exercise behavior
D: Weight loss maintenance (6 - 18 months)

Answer: C
Please select the outcome measures that correspond to the clinical trial below.
Title: Physical Activity Promotion in Breast Cancer Survivors: A Population Based Randomized Controlled Trial
Brief Summary: Over 30 studies have shown that exercise can improve physical fitness, reduce fatigue, increase functioning, and enhance overall quality of life (QoL) in breast cancer survivors both during and after treatments. Research has also shown, however, that breast cancer survivors experience a significant reduction in physical activity during treatments that is not recovered even years after treatments are completed. The objectives of this study are to examine the effects of two behavior change interventions (a step pedometer and printed materials) on physical activity, social cognitive variables, and QoL in a population-based sample of breast cancer survivors. Approximately 300 breast cancer survivors living in Northern Alberta will be randomized to one of four groups: (1) an exercise recommendation only group (viewed as the current standard of care), (2) an exercise recommendation plus pedometer group, (3) an exercise recommendation plus printed materials group, and (4) an exercise recommendation plus pedometer and printed materials group. Our primary hypothesis is that participants receiving the combined pedometer and printed materials intervention will report the greatest change in physical activity. Our secondary hypotheses are that these interventions will also result in improved QoL and more positive social cognitive beliefs about exercise in breast cancer survivors. Given the geographic dispersion of our population, finding practical and sustainable interventions that employ distance medicine-based approaches may be ideal for promoting healthy activity patterns in breast cancer survivors in Northern Alberta.


Options:
A: Exercise behavior
B: Fatigue measured by Fatigue Assessment Questionnaire (FAQ) (change between baseline and week 13 (end of intervention))
C: Menopausal symptoms (6 months)
D: Quality of Life

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Trachoma Elimination With Repeated Mass Azithromycin Treatments
Brief Summary: The WHO has initiated a program to eliminate blinding trachoma by the year 2020, in large part by mass oral azithromycin distributions. It is not clear how frequently or for how long these treatments are necessary. Here we assess the frequency and duration of treatment.


Options:
A: The prevalence of ocular chlamydia infection in a village as determined by PCR
B: Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at Baseline (At baseline); Community Prevalence of Trachoma and Ocular C. Trachomatis (CT) Infection at 36 Months (3 years)
C: All-cause Mortality Rate in Children Aged 1-60 Months (24 Months); All-cause Mortality Rate in Children Aged 1-60 Months (36 months)
D: Establish the incidence of adverse events associated with the mass triple drug administration (From Day 0 to Day 15 post treatment)

Answer: A
Please select the outcome measures that correspond to the clinical trial below.
Title: Increasing Infant Preventive Health Service Delivery in an Inner City Population
Brief Summary: The study hypothesis is that case management using patient navigators ("promatoras" in the Latino community) will increase infant immunization rates and use of well child care in an inner city population of low socioeconomic status.


Options:
A: Evaluate effectiveness of population-based reminder/recall methods versus practice-based reminder/recall methods in 14 Colorado counties (rural and urban) (6 months post-intervention (December 2010))
B: Change in Infant immunization status; Change in Infant well child care status
C: Completion of 3 Doses of Pentavalent Vaccine (8 months of age)
D: seasonal influenza vaccination (up to 4 months following reminder notification)

Answer: B
Please select the outcome measures that correspond to the clinical trial below.
Title: Increasing Infant Preventive Health Service Delivery in an Inner City Population
Brief Summary: The study hypothesis is that case management using patient navigators ("promatoras" in the Latino community) will increase infant immunization rates and use of well child care in an inner city population of low socioeconomic status.


Options:
A: Change in Infant immunization status; Change in Infant well child care status
B: Proportion of Children Under 5 Years in Vulnerable Households That Have a Birth Certificate (1 year); Proportion of Children Under 5 Years in Vulnerable Households That Have Up-to-date Vaccinations (1 year); Proportion of Children Aged 6-12 Years That Attended Primary School 80% of Days in the Last Month (1 year)
C: visits by nurse midwife; prenatal exams, tetanus vaccinations, & iron tablets received by pregnant women; infant vaccinations; educational scholarships and fees for children; occurrence of village council meetings; development work in villages
D: new immunization doses (within 60 days of reminder notification)

Answer: A